반응식
[Cl:1][C:2]1[N:3]=[C:4](Cl)[C:5]2[CH:10]=[CH:9][N:8]([S:11]([C:14]3[CH:20]=[CH:19][C:17]([CH3:18])=[CH:16][CH:15]=3)(=[O:13])=[O:12])[C:6]=2[N:7]=1.[CH3:22][N:23]1[C:31]2[C:26](=[CH:27][C:28]([NH2:32])=[CH:29][CH:30]=2)[CH:25]=[N:24]1.CCN(C(C)C)C(C)C.CCOC(C)=O>O1CCOCC1.O>[Cl:1][C:2]1[N:3]=[C:4]([NH:32][C:28]2[CH:27]=[C:26]3[C:31](=[CH:30][CH:29]=2)[N:23]([CH3:22])[N:24]=[CH:25]3)[C:5]2[CH:10]=[CH:9][N:8]([S:11]([C:14]3[CH:20]=[CH:19][C:17]([CH3:18])=[CH:16][CH:15]=3)(=[O:13])=[O:12])[C:6]=2[N:7]=1참가 물질
7
반응물 4
생성물 1
시약·촉매·용매 2
실험 절차
A solution of 2,4-dichloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine (275 mg, 0.804 mmol), 1-methyl-indazol-5-ylamine (118 mg, 0.803 mmol) and DIEA (0.350 mL, 2.01 mmol) in dioxane (7 mL) was stirred at 110° C. for 20 h. EtOAc and H2O were added. The organic phase was separated, washed with 1N HCl, then with 5% NaHCO3, dried over Na2SO4, concentrated in vacuo to give 2-chloro-N-(1-methyl-1H-indazol-5-yl)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (316 mg).
후처리
- customThe organic phase was separated
- washwashed with 1N HCl
- dry with materialwith 5% NaHCO3, dried over Na2SO4
- concentrationconcentrated in vacuo
출처 및 근거
- ORD 기록
- ord-2c7cb7ab602c471eb64b3c86b0ade537
- 출처 데이터셋
- uspto-grants-2010_04
- 특허 번호
- US07705004B2
연결된 노트
불러오는 중…